Regeneron (REGN) Tops Q2 EPS by 104c, Sales Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Regeneron Reports Second Quarter 2017 Financial and Operating Results
August 3, 2017 6:30 AM EDTTARRYTOWN, N.Y., Aug. 3, 2017 /PRNewswire/ -- Â
Second quarter 2017 EYLEA® (aflibercept) Injection U.S. net sales increased 11% to $919 million versus second quarter 2016 Second quarter 2017 EYLEA global net sales(1) increased 11% to $1.46 billion versus second quarter 2016 Raised estimated full year 2017 EYLEA U.S. net sales growth guidance to approximately 10% over 2016 Kevzara® (sarilumab) approved by FDA and European Commission for adults with moderately to severely active rheumatoid arthritisRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2017 and provided a business... More
